Why the study?
Stent underexpansion increases the risk of MACE with limited available treatment options, prompting the evaluation of off-label IVL efficacy and safety.
Does Intravascular Lithotripsy improve procedural success and safety in patients with underexpanded stents?
Does Intravascular Lithotripsy improve procedural success and safety in patients with underexpanded stents?
Intravascular lithotripsy emerges as a promising and safe off-label strategy for the management of underexpanded stents, characterized by low periprocedural complications.
Answers are grounded in this paper and cite their sources.
Supports off-label IVL for underexpanded stents; leaves open need for randomized confirmation before practice change.
BACKGROUND: Stent underexpansion significantly heightens the risk of major adverse cardiac events (MACE), and available treatment options for this condition remain limited. Intravascular Lithotripsy (IVL) technology disrupts superficial and deep calcium by using localized pulsative sonic pressure waves, emerges as a promising tool for underexpanded stents. AIMS: This study examines the overall efficacy and safety of IVL, an until-now off-label modality, in the management of underexpanded stents. METHODS: Following PRISMA guidelines, we systematically explored PubMed, SCOPUS, and Cochrane databases up to April 30, 2024, for studies evaluating IVL's safety and efficacy in treating underexpanded stents. We gathered angiographic (QCA) and intracoronary imaging (OCT or IVUS) data, examining the stent's diameter stenosis (SDS), minimal lumen diameter (MLD), minimal stent area (MSA), and minimal lumen area (MLA) pre- and post-IVL application. Procedural success constituted the efficacy endpoint, while peri-procedural complications, in-hospital-30-days and long-term mortality, and MACE were safety endpoints. CONCLUSIONS: IVL demonstrates promise as a safe and effective strategy for underexpanded stent treatment, characterized by low rates of periprocedural complications. Future prospective studies are now warranted to compare IVL to other lesion preparation strategies.
No takes yet. Share an insight, caveat, or question.
Sagris et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: